Intravitreal Bevacizumab for a Subfoveal Myopic Choroidal Neovascularization in the First Trimester of Pregnancy

Abstract

In our experience, a single intravitreal bevacizumab injection administered during the first trimester of pregnancy did not provoke any complications, and was effective in myopic CNV treatment. Further studies are warranted to provide more detailed information about this treatment and the related risks in pregnant women.